The Washington Post (11/10, Cha) reports researchers in a study on SARS-CoV-2 reinfection “said a second, third or further infections can lead to health complications just as the first can.” The study published in Nature Medicine involved “an analysis of electronic medical records in the VA’s national health care database” and “found that patients with reinfections tended to have more complications in various organ systems both during their initial illness and longer term, and they were more likely to be diagnosed with long COVID than people who did not get another infection.” These findings also “applied regardless of people’s vaccination status or whether they were boosted.”

Reuters (11/10, Lapid) reports patients with reinfection “had a more than doubled risk of death and a more than tripled risk of hospitalization compared with those who were infected with COVID just once.” Also, they “had elevated risks for problems with lungs, heart, blood, kidneys, diabetes, mental health, bones and muscles, and neurological disorders.”

Related Links:

— “The Washington Post (requires login and subscription)

MedPage Today (11/10, DePeau-Wilson) reports, “A fraction of people diagnosed as having major depressive disorder (MDD) may have misdiagnosed bipolar I disorder (BP-I),” investigators concluded in a study revealing that “among more than 75,000 people surveyed online, 302 people with MDD had potentially misdiagnosed BP-I.” The findings were presented in a poster at the Neuroscience Education Institute Congress.

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (11/10, DePeau-Wilson) reports, “The belief that long-acting injectable (LAI) antipsychotics for schizophrenia should be reserved for patients with severe symptoms or adherence issues may be contributing to their underutilization,” researchers concluded in a 380-participant, “nationwide survey of psychiatric clinicians.” The survey study revealed that “low LAI prescribers were more likely to say these therapies should only be used for patients with more severe symptoms (50% vs 21% for high prescribers) or with adherence issues (82% vs 50%, respectively).” The findings were presented at the Neuroscience Education Institute Congress.

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (11/9, DePeau-Wilson) reports, “A history of violence and having an impulsive or behavioral disorder were predictors of substance use among youths admitted to a child and adolescent psychiatry inpatient unit,” investigators concluded in a study that “reviewed 1,101 patient charts.” Additionally, “patient age was…a significant predictor of substance use,” the study revealed. The findings were disclosed in a poster presentation at the Neuroscience Education Institute Congress.

Related Links:

— MedPage Today (requires login and subscription)

Healio (11/9, Weldon) reports, “Inpatient and outpatient volume increased for pediatric patients with an eating disorder following the onset of the COVID-19 pandemic,” researchers concluded after examining “data from 14 U.S. medical centers, as well as one private eating disorder program.” Following “an initial decline in admissions at the start of the pandemic lockdowns, the sites reported a significant increase in admissions of 7.2% per month through April 2021, followed by a 3.6% decrease per month through the following December.” The findings were published online Nov. 7 in JAMA Pediatrics.

Related Links:

— “Eating disorder admissions increased after start of pandemic “Rose Weldon, Healio, November 9, 2022